Home
HelpTest ID NMEM Red Blood Cell Membrane Disorders Gene Panel, Next-Generation Sequencing, Varies
Ordering Guidance
Multiple hematology gene panels are available. For more information see NHHA and Subpanel Comparison Gene List.
Customization of this panel and/or single gene analysis for any gene present on this panel is available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.
Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Additional Testing Requirements
This test is best interpreted in the context of protein studies and peripheral blood findings. Prior to sending this test, Coombs testing should be negative and consider evaluating a peripheral blood smear. This can be provided by ordering RBCME / Red Blood Cell Membrane Evaluation, Blood. Fill out the information sheet and indicate that a next-generation sequencing test was also ordered. Additionally, providing complete blood cell count data and clinical notes will allow more precise interpretation of results.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Necessary Information
1. Metabolic Hematology Next-Generation Sequencing (NGS) Patient Information is required. Testing may proceed without the patient information; however, the information aids in providing a more thorough interpretation. Ordering providers are strongly encouraged to fill out the form and send with the specimen.
2. If form not provided, include the following information with the test request: clinical diagnosis, pertinent clinical history (ie, complete blood cell count results and relevant clinical notes), and differentials based on clinical or morphologic presentation.
Specimen Required
Specimen Type: Whole blood
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Container/Tube:
Preferred: Lavender top (EDTA)
Acceptable: Yellow top (ACD)
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated
Forms
1. Metabolic Hematology Next-Generation Sequencing (NGS) Patient Information (T816) is required.
2. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing (Spanish) (T826)
3. If not ordering electronically, complete, print, and send a Benign Hematology Test Request (T755)with the specimen.
Useful For
Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of a red blood cell (RBC) membrane disorder
Second-tier testing for patients in whom previous targeted gene variant analyses were negative for a specific RBC membrane disorder
Establishing a diagnosis of a hereditary RBC membrane disorder, allowing for appropriate management and surveillance of disease features based on the gene involved, especially if splenectomy is a consideration(5)
Identifying variants within genes associated with phenotypic severity, allowing for predictive testing and further genetic counseling
Special Instructions
Method Name
Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing
Reporting Name
RBC Membrane Sequencing, NGSSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Varies | Varies | ||
Reference Values
An interpretive report will be provided.
Day(s) Performed
Varies
Report Available
28 to 42 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81405
81479
81479 (if appropriate for government payers)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| NMEM | RBC Membrane Sequencing, NGS | 103738-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 619062 | Test Description | 62364-5 |
| 619063 | Specimen | 31208-2 |
| 619064 | Source | 31208-2 |
| 619065 | Result Summary | 50397-9 |
| 619066 | Result | 82939-0 |
| 619067 | Interpretation | 59465-5 |
| 619068 | Additional Results | 82939-0 |
| 619069 | Resources | 99622-3 |
| 619070 | Additional Information | 48767-8 |
| 619071 | Method | 85069-3 |
| 619072 | Genes Analyzed | 82939-0 |
| 619073 | Disclaimer | 62364-5 |
| 619074 | Released By | 18771-6 |